

Figure 4. High expression of pleiotrophin in GSCs. **(a)** GB2 cells maintained in serum-free medium were cultured in serum-containing medium for the indicated times. > p10, GB2 cells cultured in serum-containing medium for > 10 passages. The mRNA levels of the indicated genes were evaluated by quantitative RT-PCR and shown as the fold change over mRNA levels in GB2 cells maintained in serum-free medium (left). Error bars represent the s.d. ($n = 3$). ND, not detected. Cell lysates were subjected to immunoblotting with antibodies to the indicated proteins (right). CD133 and Lgr5 could not be detected by immunoblotting because of their low expression levels. **(b)** GB2 cells maintained in serum-free medium were cultured in medium containing retinoic acid for 4 days. The mRNA levels of the indicated genes were evaluated by quantitative RT-PCR and shown as the fold change over the vehicle-treated cells (left). Error bars represent the s.d. ($n = 3$). Cell lysates were subjected to immunoblotting with antibodies to the indicated proteins (right). **(c)** Gene expression profiles of *pleiotrophin* and *SOX2* taken from the public microarray database GSE4536 (Lee *et al.*³). Data obtained with two independent probes for each gene are shown. NBE0308 and NBE1228 are GSC lines. Serum, GSCs cultured in serum-containing medium; IC, intracranial injection; SC, subcutaneous injection.




Figure 5. SOX2 directly transactivates the expression of pleiotrophin in GSCs. **(a)** GB2 cells maintained in serum-free medium were transfected with a luciferase reporter driven by the *pleiotrophin* promoter. Luciferase reporter activity is shown. Error bars represent the s.d. ($n=3$). $*P=0.0058$ by *t*-test. **(b)** Chromatin immunoprecipitation experiments with anti-SOX2 antibody were performed with GB2 cells maintained in serum-free medium. The precipitated chromatin was amplified by quantitative PCR using primers flanking the indicated gene promoters (*pleiotrophin* and *GAPDH*) or enhancer (*SOX2*) (left). The *SOX2* enhancer was used as a positive control, as *SOX2* has been reported to be autoregulated.⁵⁰ The *GAPDH* promoter was used as a negative control. Control IgG was used as a negative control (right). Error bars represent the s.d. ($n=3$). **(c)** GB2 cells maintained in serum-free medium were infected with a lentivirus expressing an shRNA-targeting *SOX2*. Cell lysates were subjected to immunoblotting with antibodies to the indicated proteins (left). The mRNA levels of the indicated genes were evaluated by quantitative RT-PCR and shown as the fold change over mRNA levels in cells expressing control shRNA (right). Error bars represent the s.d. ($n=3$). $*P=0.001$ by *t*-test.

GSCs infected with a lentivirus expressing an shRNA targeting ALK or pleiotrophin have increased MAP2 but decreased GFAP, Olig2 and Nestin levels. These results suggest that the pleiotrophin-ALK axis inhibits neural differentiation of GSCs but maintains their stem-like characteristics. It would be interesting to examine whether the pleiotrophin-ALK axis is also involved in the maintenance of normal neural stem and progenitor cells. SOX2 has also been reported to have essential roles in the neuronal differentiation of subsets of neural stem and progenitor cells.^{14,15} For example, it has been reported that SOX2 deficiency causes impaired neurogenesis and neurodegeneration in the adult mouse brain.^{41,42} Therefore, it would be interesting to investigate whether the pleiotrophin-ALK axis is also involved in the differentiation of neural stem and progenitor cells.

The ALK inhibitor crizotinib has recently been approved for the treatment of metastatic and late stage ALK-positive NSCLC having translocations of the ALK gene.^{9,10} In addition, the ALK inhibitor TAE684 has been reported to inhibit the growth of ALK-positive ALCL, neuroblastoma and NSCLC cell lines.⁴³ Thus, we speculate that ALK inhibitors may be effective for the treatment of glioblastoma. ALK has been assumed to have a role in the development and function of the central and peripheral nervous system, as ALK is abundantly expressed in the nervous system during mouse embryogenesis,⁷ which could raise concerns about the safety of such therapy. However, both ALK- and pleiotrophin-mutant mice survive as long as wild-type mice.^{7,44} In addition, although pleiotrophin is highly expressed in NSCs, it seems dispensable for their proliferation *in vivo*.⁴⁵ Furthermore, it has been reported that the most common adverse reactions of crizotinib are relatively minor, consisting of vision disorder, nausea, diarrhea, vomiting, edema and constipation.⁴⁶ Thus, compounds targeting ALK or pleiotrophin would be expected to have relatively few serious side effects due to their effects on NSCs. In addition, we imagine that antibodies or compounds that specifically target the extracellular domain of ALK or pleiotrophin could also hold promise as novel anti-tumor agents.

MATERIALS AND METHODS

Tumor specimens and primary tumor cultures

Tumor samples classified as primary glioblastoma were obtained from patients undergoing surgical treatment at the University of Tokyo Hospital with informed consent and as approved by the Institutional Review Board. Tumors were washed and mechanically and enzymatically dissociated into single cells. Tumor cells were cultured in Neurobasal medium (Life Technologies, Carlsbad, CA, USA) containing B27 supplement minus vitamin A (Life Technologies), EGF and FGF2 (20 ng/ml each; Wako Pure Chemical Industries, Osaka, Japan). For *in vitro* differentiation, tumor cells were cultured in DMEM (Dulbecco's modified Eagle's medium)/F-12 medium (Life Technologies) containing 10% fetal bovine serum or 10 μ M all-trans retinoic acid (Sigma, St. Louis, MO, USA). U87 and 293FT cells were cultured in DMEM (Nissui, Tokyo, Japan) containing 10% fetal bovine serum. Transfections were performed using Lipofectamine 2000 Reagent, Lipofectamine LTX Reagent or Lipofectamine RNAiMAX Reagent (Life Technologies).

RNAi

Silencer Select Human Extended Druggable Genome siRNA Library was purchased from Life Technologies (the list is given in Supplementary Table S1). The siRNA oligonucleotide sequences were as follows: SOX2#1 (5'-CAGUAAUUAUCGAGAUAAA-3'), and SOX2#2 (5'-AGUGGAAACUUUUGUCGGA-3').

The shRNA oligonucleotide sequences were as follows: ALK#1 (5'-GGCCU GUAUACCGGAUAAUGA-3'), ALK#2 (5'-GAAUACAGCACCCAAUACAAG-3'), pleiotrophin#1 (5'-GGAGCUGAGUGCAAACAC-3'), pleiotrophin#2 (5'-GCAACUGGAAGAAGCAUUUG-3'), and SOX2 (5'-GUAAGAAACGCAUG GAGAAA-3').

Quantitative RT-PCR

Total RNA was extracted using the NucleoSpin RNA Clean-up kit (Takara Bio Inc., Shiga, Japan) and reverse-transcribed into cDNA using PrimeScript RT Master Mix (Takara Bio Inc.). Real-time PCR was performed using LightCycler480 SYBR Green I Master and a LightCycler480 Instrument (Roche, Indianapolis, IN, USA). The results were normalized with the detected value for glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) or hypoxanthine phosphoribosyltransferase 1 (*HPRT1*). Primers used in real-time PCR were as follows: *GAPDH* forward (5'-GCACCGTCAAGGCTGA GAAC-3'), *GAPDH* reverse (5'-TGGTGAAGACGCCAGTGA-3'); *HPRT1* forward (5'-GGCAGTATAATCCAAGATGGTCAA-3'), *HPRT1* reverse (5'-GTCAAGGGCATATCCTACAACAAAC-3'); *CD133* forward (5'-AGTGGCATCGTGCA AACCTG-3'), *CD133* reverse (5'-CTCCGAATCCATTCGACGATAGTA-3'); *nestin* forward (5'-GAGGTGGCCACGTACAGG-3'), *nestin* reverse (5'-AAGCTGAGGG AAGTCTTGA-3'); *Lgr5* forward (5'-GATTCTCTGCTTACATTTGAGG-3'), *Lgr5* reverse (5'-GCAGGTGTTACAGGGTTTG-3'); *SOX2* forward (5'-TTGCTGCCTC TTTAAGACTAGGA-3'), *SOX2* reverse (5'-CTGGGGCTCAAATCTCTC-3'); *ALK* forward (5'-CACTCCAGGGAAGCATGG-3'), *ALK* reverse (5'-TCGAATGGTT GTCTGGA-3'); *pleiotrophin* forward (5'-AACTGACCAAGCCAAACCT-3'), *pleiotrophin* reverse (5'-GGTGACATCTTTAATCCAGCA-3'), *MAP2* forward (5'-TCTCTGTGTTAAGCGGAAAA-3'), *MAP2* reverse (5'-AATACACTGGGAGC CAGAGC-3'), *GFAP* forward (5'-GACCTGGCCACTGTGAGG-3'), *GFAP* reverse (5'-AGGCAGCCAGGTGTTCTC-3'), *Olig2* forward (5'-AGCTCTCAAATCGC ATCC-3'), and *Olig2* reverse (5'-ATAGTCGTCGACGCTTTCG-3').

Antibodies

Rabbit polyclonal antibody (pAb) to green fluorescence protein (GFP) and goat pAb to SOX2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit pAbs to ALK were from Cell Signaling Technology (Danvers, MA, USA). Mouse monoclonal antibody (mAb) to pleiotrophin (H-6) was from Santa Cruz Biotechnology. Mouse mAb to Nestin was from R&D systems (Minneapolis, MN, USA). Mouse mAb to GAPDH was from Millipore (Bedford, MA, USA).

Immunoblotting

Cells were lysed in lysis buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 1 mM DTT, 1 mM EDTA, 2 mM Na₃VO₄, 10 mM NaF and protease inhibitors). Lysates were fractionated by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and transferred to a PVDF (polyvinylidene difluoride) membrane (Immobilon-P, Millipore). The membrane was subjected to immunoblot analysis using alkaline phosphatase-conjugated anti-mouse immunoglobulin G (IgG) or anti-rabbit IgG (Promega, Madison, WI, USA) as secondary antibodies. Visualization was performed using the NBT/BCIP colorimetric substrate system (Promega).

Lentivirus production

A lentiviral vector (CS-Rfa-CG) expressing an shRNA driven by the H1 promoter was transfected together with the packaging vectors pCAG-HIV-gp and pCMV-VSV-G-RSV-Rev into 293FT cells. All plasmids were kindly provided by H. Miyoshi (RIKEN BioResource Center, Ibaraki, Japan). Virus supernatant was purified by ultracentrifugation at 25 000 r.p.m. for 90 min (SW28 rotor, Beckman Coulter, Brea, CA, USA). Infection efficiency was monitored by GFP expression driven by the CMV promoter.

Intracranial xenograft

One week after lentivirus infection, 1×10^4 cells were injected stereotactically into the right frontal lobe of 5-week-old nude mice (BALB/cA/J-*nu/nu*, CLEA Japn Inc., Tokyo, Japan), following administration of general anesthesia ($n = 3$ or 4). The injection coordinates were 2 mm to the right of the midline, 1 mm anterior to the coronal suture and 3 mm deep. Mice were monitored for 6 months. Survival of mice was evaluated by Kaplan-Meier analysis. *P*-values were calculated using log rank test. The distribution of tumor cells was analyzed by GFP immunostaining. Tumors were histologically analyzed after hematoxylin and eosin staining. All animal experimental protocols were performed in accordance with the guidelines of the Animal Ethics Committee of the University of Tokyo.

Immunohistochemistry

Three months after injection of cells, brains were fixed in 3.7% buffered formalin, dehydrated and embedded in paraffin. Sections (6 μ m) were rehydrated, and endogenous peroxidases were blocked by incubation in

0.3% H₂O₂ for 5 min. The primary antibody was detected using the VECTASTAIN ABC kit (Vector Laboratories, Burlingame, CA, USA). Slides were lightly counterstained with hematoxylin.

Flow cytometry

Cells were trypsinized, fixed in 70% ethanol and then stained with propidium iodide (Sigma). Cells were passed through a FACSCalibur instrument (BD Biosciences, Billerica, MA, USA).

Microarray analysis

Expression data of cells infected with a lentivirus expressing an shRNA targeting ALK or pleiotrophin were generated using HG-U133 plus 2.0 GeneChips (Affymetrix, Santa Clara, CA, USA). Normalization and analysis of the data were conducted using Gene Spring version 11.5.1 (Agilent Technologies, Santa Clara, CA, USA). Affimetrix CEL files were uploaded to GeneSpring, and RobustMulti-Array normalization was performed. Genes downregulated >1.9-fold by ALK knockdown and those downregulated >2.3-fold by pleiotrophin knockdown were termed 'ALK_signature (ALK-sig)' and 'pleiotrophin (PTN) signature (PTN-sig)' genes, respectively (the gene lists are provided in Supplementary Tables S2 and S3). BENPORATH_ES_1 were taken from the Molecular Signature Database (MSigDB).^{25,47} The Kim_Myc_module was taken from Myc human module listed in Supplementary Table S3 of Kim *et al.*²⁷ The significance of the overlap between sh-ALK, sh-PTN#1, BENPORATH_ES_1 and/or Kim_Myc_module was calculated by the hypergeometric distribution shown in Supplementary Table S4 (Tavazoie *et al.*⁴⁸). Functional characterization of these genes was performed using SPEED.⁴⁹ The data derived from microarray analysis has been deposited in the Gene Expression Omnibus database (GSE32482). The expression profiles of *pleiotrophin* and *SOX2* in patient glioblastomas, two GSC lines and glioma cell lines were taken from GSE4536 (Lee *et al.*³).

Reporter assay

Cells were transfected with a luciferase-reporter plasmid. For *in vitro* differentiation, fetal bovine serum was added to culture medium at a final concentration of 20% and cultured for an additional 24 h. Cells were lysed and firefly luciferase activity was measured with the Luciferase Reporter Assay System (Promega) and shown as the average of three measurements.

Chromatin immunoprecipitation

Cells were fixed with 1% formalin and then the reaction was stopped by the addition of glycine to a final concentration of 125 mM. Cells were lysed in chromatin immunoprecipitated lysis buffer (50 mM Tris-HCl, pH 8.0, 1% SDS, 10 mM EDTA and protease inhibitors). Lysates were sonicated to generate DNA fragments of ~1 kb in length and then diluted 10-fold to reduce the concentration of SDS to 0.1%. Immunoprecipitations were performed with an anti-SOX2 antibody. Samples were washed, reverse-crosslinked and digested by proteinase K. Purified DNA samples were analyzed by real-time PCR, and differences in the DNA content between the bound and input fractions were determined. Primers used for amplification of the gene promoters or enhancer were as follows: *pleiotrophin* forward (5'-CAGCTCTCGAGTGCAAAGC-3'), *pleiotrophin* reverse (5'-AATGGGAGGGATGAGAGGAG-3'); *GAPDH* forward (5'-TGCGTGCCAGTTGAACCAG-3'), *GAPDH* reverse (5'-AACAGGAGGAGCAGAGAGCGAAGC-3'); *SOX2* forward (5'-TGAAGACAGTCTAGTGGGAGATGT-3'), and *SOX2* reverse (5'-CTCTTTGGCCAGGAAACT-3').

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

This work was supported by the Research Program of Innovative Cell Biology by Innovative Technology (Integrated Systems Analysis of Cellular Oncogenic Signaling Networks), Grants-in-Aid for Scientific Research on Innovative Areas (Integrative Research on Cancer Microenvironment Network), Takeda Science Foundation and, in part, by Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan.

REFERENCES

- 1 Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A *et al*. Malignant astrocytic glioma: genetics, biology, and paths to treatment. *Genes Dev* 2007; **21**: 2683–2710.
- 2 Chen J, McKay RM, Parada LF. Malignant glioma: lessons from genomics, mouse models, and stem cells. *Cell* 2012; **149**: 36–47.
- 3 Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM *et al*. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. *Cancer Cell* 2006; **9**: 391–403.
- 4 Sell S. Cancer stem cells and differentiation therapy. *Tumour Biol* 2006; **27**: 59–70.
- 5 Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. *Nat Rev Cancer* 2009; **9**: 28–39.
- 6 Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. *Cancer Lett* 2004; **204**: 127–143.
- 7 Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. *Biochem J* 2009; **420**: 345–361.
- 8 Turner SD, Alexander DR. What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? *Leukemia* 2005; **19**: 1128–1134.
- 9 Camidge DR, Doebele RC. Treating ALK-positive lung cancer—early successes and future challenges. *Nat Rev Clin Oncol* 2012; **9**: 268–277.
- 10 Gandhi L, Janne PA. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. *Clin Cancer Res* 2012; **18**: 3737–3742.
- 11 Stylianou DC, Auf der Maur A, Kodack DP, Henke RT, Hohn S, Toretsky JA *et al*. Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. *Oncogene* 2009; **28**: 3296–3306.
- 12 Yuan H, Corbi N, Basilico C, Dailey L. Developmental-specific activity of the FGF-4 enhancer requires the synergistic action of Sox2 and Oct-3. *Genes Dev* 1995; **9**: 2635–2645.
- 13 Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. *Genes Dev* 2003; **17**: 126–140.
- 14 Sarkar A, Hochedlinger K. The Sox family of transcription factors: versatile regulators of stem and progenitor cell fate. *Cell Stem Cell* 2013; **12**: 15–30.
- 15 Episkopou V. SOX2 functions in adult neural stem cells. *Trends Neurosci* 2005; **28**: 219–221.
- 16 Schmitz M, Temme A, Senner V, Ebner R, Schwind S, Stevanovic S *et al*. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. *Br J Cancer* 2007; **96**: 1293–1301.
- 17 Gangemi RM, Griffiro F, Marubbi D, Perera M, Capra MC, Malatesta P *et al*. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. *Stem Cells* 2009; **27**: 40–48.
- 18 Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, Schwarz J *et al*. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. *Cancer Res* 2010; **70**: 2030–2040.
- 19 Koyama-Nasu R, Nasu-Nishimura Y, Todo T, Ino Y, Saito N, Aburatani H *et al*. The critical role of cyclin D2 in cell cycle progression and tumorigenicity of glioblastoma stem cells. *Oncogene* 2013; **32**: 3840–3845.
- 20 Mizrak D, Brittan M, Alison M. CD133: molecule of the moment. *J Pathol* 2008; **214**: 3–9.
- 21 Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M *et al*. Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature* 2007; **449**: 1003–1007.
- 22 Wurdak H, Zhu S, Romero A, Lorger M, Watson J, Chiang CY *et al*. An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. *Cell Stem Cell* 2010; **6**: 37–47.
- 23 Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. *J Biol Chem* 2002; **277**: 14153–14158.
- 24 Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S *et al*. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. *Cancer Res* 2004; **64**: 7011–7021.
- 25 Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A *et al*. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. *Nat Genet* 2008; **40**: 499–507.
- 26 Raetz EA, Perkins SL, Carlson MA, Schooler KP, Carroll WL, Virshup DM. The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas. *Am J Pathol* 2002; **161**: 875–883.
- 27 Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG *et al*. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. *Cell* 2010; **143**: 313–324.
- 28 Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T *et al*. Identification of human brain tumour initiating cells. *Nature* 2004; **432**: 396–401.

- 29 Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P *et al*. An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008; **321**: 1807–1812.
- 30 Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 2008; **455**: 1061–1068.
- 31 Ying M, Wang S, Sang Y, Sun P, Lal B, Goodwin CR *et al*. Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition. *Oncogene* 2011; **30**: 3454–3467.
- 32 Carpenter EL, Mosse YP. Targeting ALK in neuroblastoma—preclinical and clinical advancements. *Nat Rev Clin Oncol* 2012; **9**: 391–399.
- 33 Dirks WG, Fahnrich S, Lis Y, Becker E, MacLeod RA, Drexler HG. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. *Int J Cancer* 2002; **100**: 49–56.
- 34 Meng K, Rodriguez-Pena A, Dimitrov T, Chen W, Yamin M, Noda M *et al*. Pleiotrophin signals increased tyrosine phosphorylation of β -catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. *Proc Natl Acad Sci USA* 2000; **97**: 2603–2608.
- 35 Raulo E, Chernousov MA, Carey DJ, Nolo R, Rauvala H. Isolation of a neuronal cell surface receptor of heparin binding growth-associated molecule (HB-GAM). Identification as N-syndecan (syndecan-3). *J Biol Chem* 1994; **269**: 12999–13004.
- 36 Perez-Pinera P, Chang Y, Deuel TF. Pleiotrophin, a multifunctional tumor promoter through induction of tumor angiogenesis, remodeling of the tumor micro-environment, and activation of stromal fibroblasts. *Cell Cycle* 2007; **6**: 2877–2883.
- 37 Bernhardt M, Galach M, Novak D, Utikal J. Mediators of induced pluripotency and their role in cancer cells—current scientific knowledge and future perspectives. *Biotechnol J* 2012; **7**: 810–821.
- 38 Chen S, Xu Y, Chen Y, Li X, Mou W, Wang L *et al*. SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells. *PLoS One* 2012; **7**: e36326.
- 39 Leis O, Eguirra A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K *et al*. Sox2 expression in breast tumours and activation in breast cancer stem cells. *Oncogene* 2012; **31**: 1354–1365.
- 40 Kondo T, Raff M. Chromatin remodeling and histone modification in the conversion of oligodendrocyte precursors to neural stem cells. *Genes Dev* 2004; **18**: 2963–2972.
- 41 Ferri AL, Cavallaro M, Braid D, Di Cristofano A, Canta A, Vezzani A *et al*. Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. *Development* 2004; **131**: 3805–3819.
- 42 Cavallaro M, Mariani J, Lancini C, Latorre E, Caccia R, Gull F *et al*. Impaired generation of mature neurons by neural stem cells from hypomorphic Sox2 mutants. *Development* 2008; **135**: 541–557.
- 43 McDermott U, lafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S *et al*. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. *Cancer Res* 2008; **68**: 3389–3395.
- 44 Armet LE, Lauri SE, Hienola A, Croll SD, Lu Y, LeVorse JM *et al*. Enhanced hippocampal long-term potentiation in mice lacking heparin-binding growth-associated molecule. *Mol Cell Neurosci* 2001; **17**: 1014–1024.
- 45 Hienola A, Pekkanen M, Raulo E, Vantola P, Rauvala H. HB-GAM inhibits proliferation and enhances differentiation of neural stem cells. *Mol Cell Neurosci* 2004; **26**: 75–88.
- 46 Melosky B. Supportive care treatments for toxicities of anti-egfr and other targeted agents. *Curr Oncol* 2012; **19**: S59–S63.
- 47 Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA *et al*. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci USA* 2005; **102**: 15545–15550.
- 48 Tavazoie S, Hughes JD, Campbell MJ, Cho RJ, Church GM. Systematic determination of genetic network architecture. *Nat Genet* 1999; **22**: 281–285.
- 49 Parikh JR, Klinger B, Xia Y, Marto JA, Bluthgen N. Discovering causal signaling pathways through gene-expression patterns. *Nucleic Acids Res* 2010; **38**: W109–W117.
- 50 Chew JL, Loh YH, Zhang W, Chen X, Tam WL, Yeap LS *et al*. Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. *Mol Cell Biol* 2005; **25**: 6031–6046.


Supplementary Information accompanies this paper on the Oncogene website (<http://www.nature.com/onc>)



ELSEVIER

Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc

PCDH10 is required for the tumorigenicity of glioblastoma cells



Kanae Echizen^a, Mitsutoshi Nakada^{b,*}, Tomoatsu Hayashi^a, Hemragul Sabit^b, Takuya Furuta^b, Miyuki Nakai^a, Ryo Koyama-Nasu^a, Yukiko Nishimura^a, Kenzui Taniue^a, Yasuyuki Morishita^c, Shinji Hirano^d, Kenta Terai^e, Tomoki Todo^f, Yasushi Ino^f, Akitake Mukasa^f, Shunsaku Takayanagi^f, Ryohei Ohtani^f, Nobuhito Saito^f, Tetsu Akiyama^{a,*}

^a Laboratory of Molecular and Genetic Information, Institute of Molecular and Cellular Biosciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan

^b Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, 13-1, Takara-machi, Kanazawa 920-8641, Japan

^c Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

^d Department of Neurobiology and Anatomy, Kochi Medical School, Kochi University, Okoh-cho, Nangoku-City, Kochi 783-8505, Japan

^e Laboratory of Function and Morphology, Institute of Molecular and Cellular Biosciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan

^f Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan

ARTICLE INFO

Article history:

Received 19 December 2013

Available online 6 January 2014

Keywords:

Protocadherin PCDH10

OL-protocadherin

Glioblastoma

Tumorigenicity

Proliferation

ABSTRACT

Protocadherin10 (PCDH10)/OL-protocadherin is a cadherin-related transmembrane protein that has multiple roles in the brain, including facilitating specific cell–cell connections, cell migration and axon guidance. It has recently been reported that PCDH10 functions as a tumor suppressor and that its over-expression inhibits proliferation or invasion of multiple tumor cells. However, the function of PCDH10 in glioblastoma cells has not been elucidated. In contrast to previous reports on other tumors, we show here that suppression of the expression of PCDH10 by RNA interference (RNAi) induces the growth arrest and apoptosis of glioblastoma cells *in vitro*. Furthermore, we demonstrate that knockdown of PCDH10 inhibits the growth of glioblastoma cells xenografted into immunocompromised mice. These results suggest that PCDH10 is required for the proliferation and tumorigenicity of glioblastoma cells. We speculate that PCDH10 may be a promising target for the therapy of glioblastoma.

© 2014 Elsevier Inc. All rights reserved.

1. Introduction

Protocadherin10 (PCDH10)/OL-protocadherin is a transmembrane protein that has 6 cadherin domains in the extra cellular region and belongs to the $\delta 2$ -protocadherin family of proteins [1–3]. PCDH10 is concentrated at cell–cell junctions and promotes aggregation, although its aggregative strength is weaker than that of classical cadherins [4]. Furthermore, PCDH10 recruits the Nap1-WAVE complex at the sites of cell–cell contact and promotes reorganization of the actin cytoskeleton, which results in accelerated cell migration on confluent cell monolayers [5]. In neuronal cells, PCDH10 is localized along the axons, is concentrated in the growth cones and is involved in axon guidance [5,6].

It has recently been reported that CpG islands within PCDH10 are highly methylated and epigenetically silenced in many tumors, including breast cancer, nasopharyngeal, esophageal carcinoma and haematological malignancies and this is associated with poor prognosis [7–12]. It has also been reported that overexpression

of PCDH10 significantly inhibits proliferation or invasion of multiple tumor cells *in vitro* [9,11].

Glioblastoma is a highly invasive and progressive tumor type, with an overall 5-year survival rate of less than 5% [13]. In the present study, we examined whether PCDH10 also exerts a tumor suppressive function in glioblastoma cells. We unexpectedly found that PCDH10 is required for the proliferation and tumorigenicity of glioblastoma cells.

2. Materials and methods

2.1. Cell lines and tumor specimens

Following informed consent, tumor samples classified as primary glioblastoma were obtained from patients undergoing surgical treatment at Kanazawa University Hospital and the University of Tokyo Hospital as approved by the Institutional Review Board. The human astrocytoma cell lines U87, U251, T98G and LN229 (ATCC) were cultured in DMEM (GIBCO) supplemented with 10% fetal bovine serum. Cell lines GB1~16 were cultured in DMEM/F-12 containing B27 supplement (GIBCO), EGF and FGF2 (20 ng/ml each, Wako) on laminin-coated culture dishes [14–16].

* Corresponding authors. Fax: +81 76 234 4262 (M. Nakada), +81 3 5841 8482 (T. Akiyama).

E-mail addresses: mnakada@med.kanazawa-u.ac.jp (M. Nakada), akiyama@iam.u-tokyo.ac.jp (T. Akiyama).

2.2. Antibodies

Mouse monoclonal antibody (mAb) to PCDH10 (5G10) was prepared as described previously [6]. mAbs to α -tubulin, Flag M2 and Ki67 were purchased from CALBIOCHEM, Sigma–Aldrich and Leica Biosystems, respectively. Rabbit polyclonal antibody to GFP was from Santa Cruz.

2.3. Immunohistochemistry

Formalin-fixed and paraffin-embedded tissue blocks were sectioned (6 μ m thick) onto slides and then deparaffinized. Slides were microwaved for 15 min in target retrieval solution (pH 6.0; Dako). Internal peroxidases were blocked by incubation in 0.3% H₂O₂ solution in methanol for 20 min. Non-specific staining was blocked by a 30 min incubation with blocking solution (5% skim milk, 0.1% Tween20 in TBS). Sections were immunostained with the ABC kit (VECTOR). Anti-PCDH10 (5G10), anti-Ki67 and anti-GFP antibodies were used at a dilution of 1:200. Sections were exposed to diaminobenzidine peroxidase substrate (Funakoshi) for 5–10 min and counterstained with Mayer's hematoxylin. Non-immune rat IgG was used as a negative control. All images were taken by bright field microscopy AX80 (Olympus). Ki67 index was calculated as the number of Ki67-positive cells per 1.0×10^3 cells in each of 6 fields per sample.

2.4. Lentivirus production

The entry vector pENTRH1 (obtained from K. Ui-Tei), the lentiviral vector CS-Rfa-CG and the packaging vectors pCAG-HIV-gp and pCMV-VSV-G-RSV-Rev (provided by H. Miyoshi) were used for lentivirus production. The target sequences for shRNA are as follows: luciferase, 5'-GATTTCGAGTCGTCCTTAATGT-3'; DsRed, 5'-GCCCGT AATGCAGAAGAAGA-3'; human PCDH10#2, 5'-GTGCGTGGCAAC-GAAATGAAC-3'; human PCDH10#4, 5'-GAGAAGAAGCTCAACATC-TAT-3'. Infection efficiency was monitored by GFP expression driven by the CMV promoter.

2.5. Single-cell migration assay

Time-lapse images were obtained at 5-min intervals for 4 h using a microscope (IX81; Olympus) equipped with a cooled CCD camera CoolSNAP K4 (Photometrics). GB2 cells (1×10^3 cells) infected with shRNA-expressing lentiviruses for 3 days (MOI = 6) were plated on laminin-coated, glass-bottom, 24-well plates (Iwaki) and GFP signals were traced. Trace drawing and statistical analyses were performed with IMARIS Track (BitPlane) and Excel (Microsoft), respectively. The box plots were presented as described previously [5].

2.6. In vitro invasion assay

In vitro invasion assays were performed using 24-well Biocoat Matrigel invasion chambers (BD Biosciences). GB2 cells (1.0×10^5 cells per well) infected with shRNA-expressing viruses for 4 days (MOI = 3) were starved overnight with DMEM/F-12 medium and allowed to migrate toward the underside of the top chamber for 24 h. The lower chamber was filled with DMEM/F12 containing 10% FBS. Cells in the top chamber were removed and the number of infiltrated cells was counted by Cell Titer-Glo assays. Infiltrated cells were fixed with methanol and subjected to HE staining (Merck).

2.7. Cell proliferation assay

Cell viability was determined using the Cell Titer-Glo Luminescent Cell Viability Assay kit (Promega). Luminescence was measured on a Mithras LB 940 (Berthold).

2.8. Pcdh10

The full-length *PCDH10* variant 1 cDNA (obtained from Q. Tao) was subcloned into the pIRES hrGFP 3 \times Flag vector (Adgilent). 3 \times Flag tagged PCDH10 was subcloned into the pENTR4 dual selection vector (Invitrogen).

2.9. Apoptosis assay

Apoptotic cells were detected using the Annexin V-Biotin Apoptosis Detection Kit (MBL) and labeled with Streptavidin-APC conjugates (S888, Invitrogen). A minimum of 5×10^3 cells were analyzed with flow cytometer Canto II (BD Bioscience) and FlowJo 8.8.7 software (TreeStar, Ashland, OR).

2.10. Sphere formation assay

GB2 cells infected with shRNA-expressing lentiviruses (MOI = 3) for 3 days were plated on 96-well tissue culture plates (1000, 500 or 250 cells per well) and cultured for 2 weeks. Spheres were photographed by In Cell Analyzer 2000 (GE Healthcare) and analyzed by Developer 1.9.1 software (GE Healthcare).

2.11. Real time PCR

Real time PCR was performed as described previously [14]. The results were normalized to the detected values for GAPDH. Primer sequences are as follows: PCDH10 sense, 5'-AGGCCCTCACAGCACTCT-3'; antisense, 5'-GACTAGCATATCCTTTCCGTGTC-3'; GAPDH sense, 5'-TGGTGAAGACGCCAGTGA-3'; antisense, 5'-GCACCGTCAAGGCTGAGAAC-3'.

Immunoblotting analysis and tumor formation assays were performed as described previously [14].

3. Results and discussion

3.1. PCDH10 is expressed in glioblastoma cells

We established eight glioblastoma cell lines under serum-free conditions [14–16]. These cell lines retained clonogenic potential and were highly tumorigenic when transplanted into immunocompromised mice. Immunoblotting analysis with anti-PCDH10 antibody revealed that most of these cell lines expressed substantial levels of PCDH10 protein (Fig. 1A), in contrast to previous reports showing weak or no expression in many other tumor types. In particular, PCDH10 was abundantly expressed in GB2 and GB3 cells. By contrast, PCDH10 was not expressed at detectable levels in four commonly used glioblastoma cell lines, LN229, T98G, U251 and U87MG, which are cultured in serum-containing medium. Furthermore, immunohistochemical analysis showed that 11 out of 19 patient specimens (57.9%) were positive for PCDH10 (Fig. 1B and Supplementary Table 1). In addition, we found that PCDH10 was expressed in neurons but not in astrocytes or oligodendrocytes from normal human brain (data not shown).

3.2. PCDH10 is required for glioblastoma cell migration and invasion

It has been reported that PCDH10 binds to the Nap1-Wave complex and controls the migration of U251 cells [5]. We therefore




Fig. 1. Expression of PCDH10 in glioblastoma cells. (A) Lysates from glioblastoma cells were subjected to immunoblotting analysis with anti-PCDH10 antibody. LN229, T98G, U251 and U87MG were cultured in serum-containing medium, and GB1~16 cells were cultured in serum-free medium. The arrowhead indicates PCDH10. α -Tubulin was used as a control. (B) Histological examination of patients' samples. Tissue sections were stained with anti-PCDH10 antibody. Representative sections from PCDH10-positive (Left) and -negative (Right) tumors are shown. Scale bars, 20 μ m.

used time-lapse microscopy to examine whether PCDH10 plays a role in migration of glioblastoma cells cultured on laminin-coated dishes. We found that infection of GB2 cells with a lentivirus expressing an shRNA targeting PCDH10 resulted in a significant decrease in cell migratory activity (sh-luciferase vs sh-PCDH10#2, $p = 0.021$; sh-luciferase vs sh-PCDH10#4, $p = 0.00059$) (Fig. 2A and B), as well as a decrease in PCDH10 protein levels (Supplementary Fig. 1), but did not affect adhesion to laminin-coated dishes (Fig. 2C). Since glioblastoma is a highly invasive tumor [13,17], we also performed Matrigel invasion assays. We found that knock-down of PCDH10 resulted in a decrease in the invasive activity of GB2 cells (sh-luciferase vs sh-PCDH10#2, $p = 0.034$; sh-luciferase vs sh-PCDH10#4, $p = 0.042$) (Fig. 2D and E). These results suggest

that PCDH10 has the potential to promote migration and invasion of glioblastoma cells.

3.3. Knockdown of PCDH10 induces the growth arrest and apoptosis of glioblastoma cells

It has recently been shown that overexpression of PCDH10 inhibits the proliferation of multiple tumor cells *in vitro* [9,11]. We therefore investigated the significance of PCDH10 in the proliferation of three glioblastoma cell lines, GB2, GB3 and GB16, in which PCDH10 is abundantly expressed (Fig. 1A). Cell Titer-Glo assays revealed that infection of these cells with a lentivirus expressing an shRNA targeting PCDH10 resulted in a decrease in




Fig. 2. PCDH10 is required for the migration and invasion of glioblastoma cells. (A and B) GB2 cells were infected with the indicated shRNA-expressing lentivirus at MOI = 6. Time-lapse images were taken at 5-min intervals for 4 h. (A) One representative field of each sample. Tracks of individual cells that neither divided nor contacted other cells were analyzed. Scale bar, 400 μ m. (B) Images were taken from 9 fields per sample. The number of cells analyzed was: sh-luciferase, $n = 140$; sh-DsRed, $n = 131$; sh-PCDH10#2, $n = 138$; sh-PCDH10#4, $n = 158$. Bars indicate medians and magenta dots indicate means ($n = 4$). $**p < 0.01$. (C) GB2 cells were infected with the indicated shRNA expressing lentivirus at MOI = 6. Cells were re-plated 5 days after the infection. Adherent cell numbers were determined by Cell Titer-Glo assays. Dishes coated with 1% BSA were used as controls. Results are shown as average of 4 wells \pm SD. $*p < 0.05$. (D and E) GB2 cells were infected with the indicated shRNA-expressing lentivirus at MOI = 3. 1.0×10^5 cells were allowed to migrate toward the underside of the top chamber for 24 h. (D) HE staining of the invaded cells. Scale bar, 100 μ m. (E) Cell Titer-Glo assays of the invaded cells. Results are shown as average of 3 wells \pm SD. $*p < 0.05$.

their proliferation (Fig. 3A). By contrast, overexpression of PCDH10 did not affect proliferation of T98G or U251 cells, which do not express detectable levels of PCDH10 protein (Supplementary Fig. 2). We also performed AnnexinV assays and found that knockdown of PCDH10 induced apoptosis of GB2 cells (Fig. 3B and C). We next performed sphere formation assays to clarify the role of PCDH10 in the self-renewal capacity of glioblastoma cells. We found that knockdown of PCDH10 by shRNA resulted in significant inhibition of sphere formation (Fig. 3D and E). Thus, PCDH10 may be critical for the proliferation, survival and self-renewal of glioblastoma cells.

3.4. Knockdown of PCDH10 suppresses the tumorigenicity of glioblastoma cells

To clarify the role of PCDH10 in the tumorigenicity of glioblastoma cells, we orthotopically transplanted GB16 cells that had been infected with a lentivirus expressing GFP and an shRNA targeting PCDH10 into the frontal lobe of nude mice. We found that the mice transplanted with PCDH10-knockdown GB16 cells survived longer than control mice (sh PCDH10#2, log-rank test $p=0.042$; sh PCDH10#4, log-rank test $p=0.00031$) (Fig. 4A). Histological studies revealed that all mice transplanted with




Fig. 3. PCDH10 is required for the proliferation, survival and self-renewal of glioblastoma cells. (A) Cell Titer-Glo assays were performed with GB2, GB3 or GB16 cells infected with a lentivirus expressing an shRNA targeting PCDH10 (MOI = 3). Results are shown as average of 5 wells \pm SD. (B) AnnexinV assays were performed with GB2 cells that had been infected with a lentivirus expressing an shRNA targeting PCDH10 for 8 days. (C) AnnexinV-positive populations in (B) are shown. Results are shown as the mean \pm SD ($n=3$). At least 5000 cells were analyzed per sample. $**p < 0.01$. (D and E) Sphere formation assays were performed with GB2 cells that had been infected with a lentivirus expressing an shRNA targeting PCDH10 for 17 days. (D) Bright field images of spheres. (E) Results are shown as average of 6 wells \pm SD. $**p < 0.01$.




Fig. 4. PCDH10 is required for the tumorigenicity of glioblastoma cells. (A) Kaplan–Meier survival curves of mice transplanted with 1.0×10^4 GB16 cells infected with a lentivirus expressing GFP and shRNA targeting PCDH10 or luciferase (control) (MOI = 1; $n = 8$ for shPCDH10#2 and luciferase; $n = 6$ for shPCDH10#4). (B) Histological analysis of tumors harvested from the mice in (A). Tissue sections were stained with HE or anti-GFP antibody. General views (Upper Panel; Scale bar, 2.0 mm) and magnified views (Middle and Lower panels; Scale bars, 100 μ m) of the region around the corpus callosum in the right hemisphere (near the injection point, black squares in the upper panel). (C and D) Immunohistochemical analysis of tumors harvested from the mice in (A). Tissue sections were stained with anti-GFP and anti-Ki-67 antibodies. Scale bars, 100 μ m. (D) Ki67 indices of the brain sections. 1.0×10^3 cells were counted in each field. Results are shown as average of 6 fields \pm SD. ** $p < 0.01$.

GB16 cells had developed tumors with diffuse infiltration into surrounding brain tissues, one of the hallmark features of glioblastoma (Fig. 4B). The density of GFP-expressing cells (injected tumor cells) was slightly lower in the brains of the mice transplanted with PCDH10-knockdown GB16 cells compared to those of control mice (Fig. 4B). Furthermore, we observed that the number of Ki67-positive cells was significantly reduced in the brains of the mice transplanted with PCDH10-knockdown GB16 cells compared to those of control mice (sh-luciferase, $14.0 \pm 2.0\%$; sh-PCDH10#2, $2.2 \pm 1.1\%$; sh-PCDH10#4, $3.7 \pm 0.64\%$) (Fig. 4C and D). These results suggest that knockdown of PCDH10 suppresses the proliferation of glioblastoma cells and extends the survival of tumor-bearing mice.

These results show that PCDH10 is required for the proliferation and tumorigenicity of glioblastoma cells. This suggests that PCDH10 may function differently at the molecular level in glioblastoma cells compared to other tumor cell types. This may mean that PCDH10 associates with different molecules and elicits different downstream signals in glioblastoma cells than it does in other tumor cells. The molecular mechanisms underlying this functional difference remain to be elucidated. It also remains to be investigated whether PCDH10 expression levels are associated with the classification and prognosis of glioblastoma patients. Finally, we speculate that PCDH10 may be a potential therapeutic target for glioblastoma. In particular, monoclonal antibodies that target the extracellular domain of PCDH10 could hold promise as novel anti-tumor reagents.

Acknowledgments

This work was supported by Research Program of Innovative Cell Biology by Innovative Technology (Integrated Systems Analysis of Cellular Oncogenic Signaling Networks), Grants-in-Aid for Scientific Research on Innovative Areas (Integrative Research on

Cancer Microenvironment Network), Project for Development of Innovative Research on Cancer Therapeutics, Grant-in-Aid for Scientific Research (C-23592117) from the Japan Society for the Promotion of Science (M. Nakada) and Foundation for Promotion of Cancer Research (M. Nakada), Takeda Science Foundation, Kato Memorial Bioscience Foundation and in part by Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bbrc.2013.12.138>.

References

- [1] Q. Wu, T. Maniatis, A striking organization of a large family of human neural cadherin-like cell adhesion genes, *Cell* 97 (1999) 779–790.
- [2] S. Hirano, M. Takeichi, Cadherins in brain morphogenesis and wiring, *Physiol. Rev.* 92 (2011) 597–634.
- [3] W.V. Chen, T. Maniatis, Clustered protocadherins, *Development* 140 (2013) 3297–3302.
- [4] S. Hirano, Q. Yan, S.T. Suzuki, Expression of a novel protocadherin, OL-protocadherin, in a subset of functional systems of the developing mouse brain, *J. Neurosci.* 19 (1999) 995–1005.
- [5] S. Nakao, A. Platek, S. Hirano, M. Takeichi, Contact-dependent promotion of cell migration by the OL-protocadherin-Nap1 interaction, *J. Cell Biol.* 182 (2008) 395–410.
- [6] M. Uemura, S. Nakao, S.T. Suzuki, M. Takeichi, S. Hirano, OL-protocadherin is essential for growth of striatal axons and thalamocortical projections, *Nat. Neurosci.* 10 (2007) 1151–1159.
- [7] K. Miyamoto, T. Fukutomi, S. Akashi-Tanaka, T. Hasegawa, T. Asahara, T. Sugimura, T. Ushijima, Identification of 20 genes aberrantly methylated in human breast cancers, *Int. J. Cancer* 116 (2005) 407–414.
- [8] J. Ying, H. Li, T.J. Seng, C. Langford, G. Srivastava, S.W. Tsao, T. Putti, P. Murray, A.T. Chan, Q. Tao, Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation, *Oncogene* 25 (2006) 1070–1080.